Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 26.74 USD 0.11% Market Closed
Market Cap: 151.5B USD
Have any thoughts about
Pfizer Inc?
Write Note

Pfizer Inc
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pfizer Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Pfizer Inc
NYSE:PFE
Other Long-Term Assets
$18.6B
CAGR 3-Years
25%
CAGR 5-Years
27%
CAGR 10-Years
15%
Johnson & Johnson
NYSE:JNJ
Other Long-Term Assets
$19.8B
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
9%
Bristol-Myers Squibb Co
NYSE:BMY
Other Long-Term Assets
$6.2B
CAGR 3-Years
38%
CAGR 5-Years
13%
CAGR 10-Years
13%
Merck & Co Inc
NYSE:MRK
Other Long-Term Assets
$13.3B
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
7%
Zoetis Inc
NYSE:ZTS
Other Long-Term Assets
$624m
CAGR 3-Years
41%
CAGR 5-Years
31%
CAGR 10-Years
18%
Eli Lilly and Co
NYSE:LLY
Other Long-Term Assets
$12.5B
CAGR 3-Years
25%
CAGR 5-Years
22%
CAGR 10-Years
18%
No Stocks Found

Pfizer Inc
Glance View

Market Cap
151.5B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.

PFE Intrinsic Value
24.76 USD
Overvaluation 7%
Intrinsic Value
Price

See Also

What is Pfizer Inc's Other Long-Term Assets?
Other Long-Term Assets
18.6B USD

Based on the financial report for Sep 29, 2024, Pfizer Inc's Other Long-Term Assets amounts to 18.6B USD.

What is Pfizer Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
15%

Over the last year, the Other Long-Term Assets growth was 8%. The average annual Other Long-Term Assets growth rates for Pfizer Inc have been 25% over the past three years , 27% over the past five years , and 15% over the past ten years .

Back to Top